HC Wainwright reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a $17.00 target price on the stock. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2024 earnings at ($0.52) EPS, Q4 2024 earnings at ($0.52) EPS, FY2025 earnings at ($2.05) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.78 EPS.
Several other research firms have also issued reports on VIGL. JMP Securities reiterated a market outperform rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, April 18th. Wedbush reissued an outperform rating and set a $23.00 price target on shares of Vigil Neuroscience in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Vigil Neuroscience presently has an average rating of Moderate Buy and an average target price of $16.60.
Check Out Our Latest Stock Report on VIGL
Vigil Neuroscience Price Performance
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. Equities research analysts anticipate that Vigil Neuroscience will post -2.1 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Strs Ohio bought a new stake in shares of Vigil Neuroscience during the fourth quarter worth $27,000. Vanguard Group Inc. boosted its stake in shares of Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after purchasing an additional 95,276 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Vigil Neuroscience in the 2nd quarter valued at about $26,000. Renaissance Technologies LLC raised its stake in shares of Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.
Vigil Neuroscience Company Profile
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Articles
- Five stocks we like better than Vigil Neuroscience
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Business Services Stocks Investing
- MarketBeat Week in Review – 8/12 – 8/16
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.